title: Recurrence of differentiated thyroid carcinoma during full TSH suppression: is the tumor now thyroid hormone dependent?
abstract: Well-standardized primary treatment and long-term management of differentiated thyroid carcinoma (DTC) include lowering or suppression of host thyrotropin (TSH) with exogenous L-thyroxine (T4). This treatment recognizes the trophic action of TSH on DTC cells. Suppression of endogenous TSH with T4 is continued in recurrent disease. However, T4 can induce proliferation of follicular and papillary thyroid carcinoma cell lines and of other human carcinoma cells. The proliferative mechanism is initiated at a cell surface receptor for T4 on integrin αvβ3, a receptor by which the hormone also inhibits p53-dependent apoptosis in tumor cells. In recurrent DTC with satisfactory suppression of endogenous TSH, we discuss here the possibility that the tumor is no longer TSH dependent and that T4 has become a critical growth factor for the cancer.
authors.affiliation: Department of Medicine, Albany Medical College, Albany, NY, USA, pdavis.ordwayst@gmail.com.
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Davis
authors.forename: Aleck
authors.initials: A
authors.lastname: Hercbergs
authors.forename: Mary K
authors.initials: MK
authors.lastname: Luidens
authors.forename: Hung-Yun
authors.initials: HY
authors.lastname: Lin
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D019468:Disease Management; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000378:metabolism; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local; D013963:Thyroid Hormones / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D013972:Thyrotropin / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D039302:Integrin alphaVbeta3; D013963:Thyroid Hormones; D013972:Thyrotropin